RxDoctor Payments Data

Bernardo Rodrigues, MD

Neurology · Farmington, CTNPI 1477886356

Payments from drug & device makers

$42,034in general payments, 2019–2025

Across 9 payments — averaging $4670.48 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$41K
  • Medtronic$337
  • AbbVie$125
  • Boston Scientific$108
  • Acadia Pharmaceuticals Inc$75
  • MDD US Operations, LLC$22

What the payments were for

  • Food & beverage$667100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$42,034 in reported general payments places this provider in the 75th percentile of 280 neurology providers in Connecticut.

See all neurology providers in Connecticut

Medicare billing

Part B allowed, 2024
$161,324
Medicare patients
164
Services billed
17,892

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
NuplazidPimavanserin Tartrate76$417,692
IngrezzaValbenazine Tosylate18$145,982
GocovriAmantadine Hcl50$90,259
NeuproRotigotine49$60,261
RytaryCarbidopa/Levodopa31$33,869
Nurtec OdtRimegepant Sulfate11$28,916
NourianzIstradefylline12$23,163
Carbidopa-LevodopaCarbidopa/Levodopa457$19,056
Primidone152$5,321
Quetiapine Fumarate88$5,154
Gabapentin213$5,062
Rivastigmine21$4,894
Carbidopa-Levodopa ErCarbidopa/Levodopa144$4,318
Carbidopa-Levodopa-EntacaponeCarbidopa/Levodopa/Entacapone14$3,651
Entacapone16$3,413

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Acadia Pharmaceuticals IncNuplazid$75$417,69276 claims
MDD US Operations, LLCGocovri$22$90,25950 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 280 neurology providers in Connecticut.

Other neurology in Farmington

See the full list for Connecticut

Where these figures come from

Is this you, or does something look wrong? →